Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies
Abstract Background Chimeric antigen receptor T cell (CAR-T) therapy achieves high remission rates in lymphoid malignancies, but its long-term efficacy is limited by poor persistence and T cell exhaustion. Pomalidomide, an immunomodulatory drug (IMiD), demonstrates clinical synergy with CAR-T therap...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer
2025-12-01
|
| Seri Bilgileri: | Cancer Immunology, Immunotherapy |
| Konular: | |
| Online Erişim: | https://doi.org/10.1007/s00262-025-04247-1 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|